In this context, we have previously shown that IDH1 mutation primes AML cells to the myeloid differentiation pathway through a 2-HG-mediated activation of the transcription factor CEBPα that sensitizes IDH1 mutant (IDH1MUT) AML cells to differentiation therapy using all-trans retinoic acid (ATRA) [4]. This evidence concerns the gene IDH1 and acute myeloid leukemia.